Trial Profile
A Randomized Phase 2 Study of Single Agent GSK2118436 (BRAFi) vs. Combination Regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 01 Oct 2022 Results published in the Thyroid
- 26 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 26 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.